206 related articles for article (PubMed ID: 34667112)
1. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract][Full Text] [Related]
2. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
[TBL] [Abstract][Full Text] [Related]
3. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
4. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H
Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
Jaiswal A; Jaiswal A; Williamson EA; Gelfond J; Zheng G; Zhou D; Hromas R
Cancer Chemother Pharmacol; 2023 Jan; 91(1):89-95. PubMed ID: 36346454
[TBL] [Abstract][Full Text] [Related]
6. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Banerjee S; Choi M; Aboukameel A; Wang Z; Mohammad M; Chen J; Yang D; Sarkar FH; Mohammad RM
Pancreas; 2010 Apr; 39(3):323-31. PubMed ID: 19823097
[TBL] [Abstract][Full Text] [Related]
8. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
9. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.
Celli JP; Solban N; Liang A; Pereira SP; Hasan T
Lasers Surg Med; 2011 Sep; 43(7):565-74. PubMed ID: 22057484
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
Takahashi H; Chen MC; Pham H; Matsuo Y; Ishiguro H; Reber HA; Takeyama H; Hines OJ; Eibl G
Biochim Biophys Acta; 2013 Dec; 1833(12):2980-2987. PubMed ID: 23954445
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
Zhang C; Cai TY; Zhu H; Yang LQ; Jiang H; Dong XW; Hu YZ; Lin NM; He QJ; Yang B
Mol Cancer Ther; 2011 Jul; 10(7):1264-75. PubMed ID: 21566062
[TBL] [Abstract][Full Text] [Related]
16. A selective BCL-X
Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
[TBL] [Abstract][Full Text] [Related]
17. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
Zhou Y; Liu H; Xue R; Tang W; Zhang S
Dig Dis Sci; 2018 Dec; 63(12):3367-3375. PubMed ID: 30155839
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
19. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]